Crossing SOD1G93A mice with mice overexpressing Nrf2 selectively in astrocytes significantly delayed disease onset and extended survival of SOD1G93A transgenic mice [167], making Nrf2 a possible therapeutic target in ALS. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.